



NCPE Plain English Summary

Drug name: Lutetium (^{177}Lu) oxodotreotide (*pronounced: loo-TEE-shee-um OX-odo-tree-o-tide*) for the treatment of unresectable or metastatic, progressive, well differentiated (Grade 1 and Grade 2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours in adults.

Brand name: Lutathera[®]

What is the NCPE?

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe, and cost-effective (value for money) treatments for patients.

How do we make our recommendations?

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

What is lutetium (^{177}Lu) oxodotreotide used for?

Lutetium (^{177}Lu) oxodotreotide is a cancer medicine for treating tumours in the gut known as gastroenteropancreatic neuroendocrine tumours. It is a radiopharmaceutical (a medicine that

emits a small amount of radioactivity). It is used to treat tumours that cannot be removed by surgery, have spread to other parts of the body, or are not responding to treatment. The medicine is only for tumours that have receptors called somatostatin receptors on their cell surfaces.

What recommendation has the NCPE made to the HSE?

We have recommended that the HSE should consider not funding lutetium (^{177}Lu) oxodotreotide. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional [criteria](#) outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have received a Patient Organisation Submission from NET Patient Network Ireland about lutetium (^{177}Lu) oxodotreotide and shared it with the HSE. This submission will form part of the data that the HSE considers.

Why did we make this recommendation?

After reviewing the data presented by the pharmaceutical company, we concluded that lutetium (^{177}Lu) oxodotreotide not be considered for reimbursement. We have completed a full health technology assessment for this medicine. We recommend that the HSE consider not providing this medicine. This is because we did not receive enough information to clearly assess how well the medicine works compared with other ways of managing this condition or whether the medicine is value for money.

Next steps

When the HSE receives our recommendation, it will look at all the relevant data about lutetium (^{177}Lu) oxodotreotide. The HSE makes the final decision on reimbursement.

Where can I get more information?

You can get more information about lutetium (^{177}Lu) oxodotreotide from the following online options:

- the NCPE Technical Summary Document
- lutetium (^{177}Lu) oxodotreotide European Public Assessment Report (EPAR) – [Summary for the public](#) or
- searching for lutetium (^{177}Lu) oxodotreotide on our website (www.ncpe.ie);

- searching for lutetium (¹⁷⁷Lu) oxodotreotide on the European Medicines Agency (EMA) website (www.ema.europa.eu).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine.

Date published: February 2020